This month's edition of Medtech Insight's Starts & Stops shows that technology to repair or replace defective heart valves, either with surgery or catheter-based interventions, remains a hot area of research and development for the major cardiovascular device companies.
Abbott Laboratories Inc. has dominated the minimally-invasive mitral valve repair market with its MitraClip device, a catheter-delivered clip that holds two valve leaflets together to minimize mitral regurgitation. Now Abbott is now bringing that same concept to the treatment of tricuspid regurgitation with its Tricuspid Valve Repair System (TVRS). In early August, Abbott announced the start of